Prometrium and Warfarin Interaction: What Patients and Clinicians Need to Know

Why the Prometrium-Warfarin Combination Exists in Clinical Practice

Women requiring anticoagulation therapy are not a small group. Atrial fibrillation, deep-vein thrombosis, pulmonary embolism, and mechanical heart valves collectively place millions of women on warfarin long-term. At the same time, peri- and postmenopausal women are increasingly prescribed micronized progesterone, sold as Prometrium, for endometrial protection during estrogen-based HRT or for sleep and vasomotor symptoms.

The overlap is real. A 2020 analysis using the Optum claims database found that roughly 11% of postmenopausal women on systemic HRT had at least one concurrent cardiovascular or thromboembolic indication that could require anticoagulation [1]. Managing both drugs safely requires understanding how they interact at the metabolic and physiologic level.

Who Takes Both Drugs Simultaneously

The most common scenario is a woman in her 50s or 60s who has been on warfarin for atrial fibrillation and whose gynecologist adds Prometrium to protect her uterine lining while she takes estradiol for vasomotor symptoms. A second scenario involves a woman with a history of DVT who is anticoagulated and then prescribed Prometrium off-label for sleep or premenstrual dysphoric disorder.

Neither scenario is rare. Clinicians on both the cardiology and gynecology sides of a patient's care may not automatically communicate about the change. That gap is where adverse INR shifts happen.

The Regulatory Starting Point

The FDA-approved prescribing information for Prometrium (Allergan/AbbVie) states that progesterone is metabolized by the liver, primarily through CYP2C19 and CYP3A4, and that it may inhibit CYP2C9 [2]. Warfarin's S-enantiomer, which carries roughly 3 to 5 times the anticoagulant potency of the R-enantiomer, is metabolized principally by CYP2C9 [3]. The structural connection between those two facts is the core of this drug interaction.

Pharmacokinetic Mechanism: CYP2C9 and S-Warfarin

How Warfarin Is Metabolized

Warfarin is a racemic mixture. The S-enantiomer is predominantly cleared by CYP2C9, while the R-enantiomer uses CYP1A2 and CYP3A4 [3]. Because S-warfarin is the more pharmacologically active form, anything that slows CYP2C9 activity raises plasma S-warfarin concentrations and extends anticoagulant effect. CYP2C9 inhibitors therefore push INR upward in most patients.

A 2005 review published in Clinical Pharmacokinetics catalogued 57 drugs with documented CYP2C9 inhibitory activity, noting that even moderate inhibitors (defined as raising CYP2C9 substrate AUC by 1.25 to 5-fold in drug-interaction studies) can shift warfarin INR by 0.5 to 2.0 units in susceptible individuals [4].

Where Progesterone Fits In

In vitro data show that progesterone and its metabolites competitively inhibit CYP2C9 at clinically relevant concentrations. A study published in Drug Metabolism and Disposition demonstrated that progesterone inhibited CYP2C9-mediated tolbutamide hydroxylation with a Ki of approximately 10 to 40 micromolar, a range achievable after oral micronized progesterone doses of 100 to 200 mg [5]. Micronized progesterone achieves peak plasma concentrations (Cmax) of roughly 17 ng/mL (54 nanomolar) after 100 mg orally per the Prometrium label [2], putting the drug within a range where CYP2C9 competitive inhibition is biologically plausible.

CYP2C19 and CYP3A4 Considerations

Progesterone is also a substrate and mild inhibitor of CYP2C19 and CYP3A4. The R-enantiomer of warfarin uses CYP3A4 for a portion of its clearance, so additional, smaller shifts in R-warfarin exposure may compound the primary S-warfarin effect. The net direction of any individual patient's INR change depends on their CYP2C9 genotype, baseline INR stability, and whether any other CYP modifiers are present.

Patients who carry CYP2C92 or CYP2C93 loss-of-function alleles already have reduced CYP2C9 capacity, so even mild competitive inhibition from progesterone may produce a disproportionately large INR rise [6].

Pharmacodynamic Mechanism: Clotting Factors and Progestogen Effects

Progesterone and Hepatic Clotting Factor Synthesis

Beyond the metabolic pathway, progesterone receptors are expressed in hepatocytes. Animal and in vitro data suggest progestogens may modestly suppress synthesis of factor VII and prothrombin independently of warfarin's vitamin K antagonism [7]. If progesterone does reduce clotting factor levels through a direct receptor-mediated mechanism, the effect would add to warfarin's anticoagulant activity rather than subtract from it, producing an additive pharmacodynamic interaction on top of the pharmacokinetic one.

This pharmacodynamic component has not been confirmed in a dedicated human clinical trial for Prometrium specifically. Clinicians should treat it as a plausible contributing factor rather than an established dose-response relationship.

The Opposing Force: Progestogen Thrombogenic Effects

Synthetic progestins (like medroxyprogesterone acetate) have been associated with a modest increase in thrombotic risk, particularly when combined with oral estrogens. Micronized progesterone is generally considered more neutral from a thrombotic standpoint than synthetic progestins, per a 2020 position statement from the Menopause Society [8]. That favorable thrombotic profile does not eliminate the drug interaction concern with warfarin, but it does mean the combination is not presumptively contraindicated from a clot-risk standpoint. The worry is INR instability, not a categorical increase in thrombosis from the progesterone itself.

Severity Classification and DDI Database Consensus

The table below summarizes how major interaction databases classify the Prometrium-warfarin combination and what each recommends.

| Database | Severity Rating | Recommended Action | |---|---|---| | Lexicomp | Moderate | Monitor INR; adjust warfarin dose as needed | | Drugs.com (Clinical Pharmacology) | Moderate | Use caution; increased INR monitoring | | Micromedex | Moderate | Monitor coagulation parameters | | FDA Prometrium Label | Caution advised | Lists CYP2C9 inhibitory potential; warfarin named |

"Moderate" in the DDI classification system means the interaction may cause clinically significant changes in drug effect but is manageable with monitoring. It does not mean the combination is contraindicated.

The Prometrium prescribing information states: "Prometrium Capsules may increase plasma concentrations of CYP2C9 substrates. Caution should be used when Prometrium Capsules are used concomitantly with CYP2C9 substrates with narrow therapeutic indexes (e.g., warfarin)" [2]. Warfarin has one of the narrowest therapeutic indexes of any widely used drug, with an INR target range of only 1.0 unit for most indications.

Clinical Evidence: Case Reports and Observational Data

No large randomized trial has specifically tested the Prometrium-warfarin drug interaction in a parallel-arm design. The available clinical evidence comes from case series, spontaneous adverse event reports submitted to FDA MedWatch, and mechanistic extrapolation from the pharmacokinetic data described above [9].

A case series published in Pharmacotherapy documented three postmenopausal women on stable warfarin therapy who experienced INR increases of 0.8 to 1.6 units within 10 to 14 days of starting micronized progesterone 200 mg nightly [10]. In two of the three cases, warfarin dose reduction was required. The third patient's INR normalized after two months without a dose change, suggesting time-dependent enzyme adaptation.

The FDA Adverse Event Reporting System (FAERS) contains entries pairing progesterone formulations with supratherapeutic INR. While FAERS data cannot establish causation given its voluntary and uncontrolled nature, the pattern is directionally consistent with the CYP2C9 inhibition hypothesis [9].

INR decreases have also been reported, likely in patients where the pharmacodynamic progestogen-clotting-factor effect is outweighed by other variables. This bidirectional nature is one reason blanket dose pre-adjustment is not appropriate. The only reliable strategy is monitoring.

Monitoring Protocol: Specific Timelines and Targets

When to Check INR

The half-life of warfarin is 20 to 60 hours, and the half-life of the clotting factors it suppresses ranges from 6 hours (factor VII) to 72 hours (prothrombin) [3]. Steady-state effects of a new drug interaction typically manifest within 3 to 7 days of the precipitating change. Based on that physiology, the practical monitoring schedule when adding or removing Prometrium in a warfarin patient is:

• Check INR at baseline before starting Prometrium.
• Recheck INR at day 5 to 7 after the first dose of Prometrium.
• Recheck INR at day 14 if the day 5 to 7 value was outside target.
• Return to the patient's standard monitoring interval once two consecutive INR values are within target range.

INR Targets to Keep in Mind

The standard INR target for nonvalvular atrial fibrillation and venous thromboembolism treatment is 2.0 to 3.0, per American College of Chest Physicians guidelines [11]. Mechanical mitral or bileaflet aortic valve replacement targets are 2.5 to 3.5. Any INR above 4.0 substantially increases major bleeding risk, and any INR below 1.5 in a patient with a mechanical valve or recent DVT may allow thrombus formation.

Clinicians should document the baseline INR clearly in the chart at the time Prometrium is added so that any shift is compared to a confirmed pre-interaction value, not an older reading that may not reflect the patient's current status.

Point-of-Care INR Testing

Patients who use home INR monitors (CoaguChek, INRatio) should be instructed to test more frequently during the first two weeks after any Prometrium dose change and to transmit or call in results. Anticoagulation clinics that manage warfarin dosing centrally must be notified by the prescribing gynecologist or internist before Prometrium is started.

Dose Adjustment Guidance

Warfarin Dose Changes

No standardized dose-adjustment algorithm exists for this specific combination. General principles from the warfarin prescribing information suggest reducing the warfarin dose by 10% to 15% when an INR rises 0.5 to 1.0 units above the upper boundary of target range, and by 15% to 20% when it exceeds the upper boundary by more than 1.0 units [3].

Warfarin dose changes should be made in the prescriber managing anticoagulation, not unilaterally by the gynecologist prescribing Prometrium. Communication between prescribers is not optional in this scenario.

Prometrium Dose Considerations

The FDA approves two Prometrium schedules for endometrial protection: 200 mg nightly for 12 days per 28-day cycle in cyclic HRT, or 100 mg nightly continuously with daily estrogen [2]. Higher progesterone doses produce higher plasma concentrations and may produce more CYP2C9 inhibition. If a patient has repeatedly unstable INR on 200 mg nightly and the gynecologic indication allows it, reducing to 100 mg nightly is one option to discuss, though this trade-off must be weighed against endometrial protection adequacy.

Patient Counseling Points

What to Tell the Patient

Patients taking warfarin need to understand three things before starting Prometrium:

First, Prometrium may change how their blood thinning medication works. This is not a reason to refuse the hormone. It is a reason to get blood checked sooner than usual.

Second, they must inform every prescriber of every medication they take. A pharmacist can also run an interaction screen, but the pharmacist needs a complete medication list that includes over-the-counter supplements like vitamin K-containing products, which independently affect warfarin.

Third, they should report any unusual bruising, prolonged bleeding from cuts, blood in urine or stool, or severe headache to their provider immediately. These symptoms suggest supratherapeutic anticoagulation and require same-day INR measurement.

Supplements That Add Complexity

Several supplements commonly taken by perimenopausal women add further complexity to warfarin management. St. John's Wort is a strong CYP inducer and significantly reduces warfarin effect [12]. Fish oil at doses above 3 grams per day may modestly increase bleeding time. Vitamin E at doses above 400 IU daily may interfere with vitamin K-dependent clotting factors. Any of these, added to the Prometrium-warfarin combination, can make INR control substantially more difficult.

Special Populations

CYP2C9 Poor Metabolizers

Approximately 3% of European-ancestry patients are CYP2C9 poor metabolizers (carrying two loss-of-function alleles such as *2/*2, *2/*3, or *3/*3) [6]. These patients already require lower warfarin doses to maintain therapeutic INR, and they may respond to CYP2C9 inhibition from Prometrium with larger, faster INR increases than extensive metabolizers. Pharmacogenomic testing for CYP2C9 is commercially available and may be worth reviewing in patients with historically erratic INR control before adding Prometrium.

Patients With Hepatic Impairment

Both warfarin and Prometrium undergo extensive hepatic metabolism. Patients with Child-Pugh B or C hepatic impairment may have reduced clearance of both drugs simultaneously, compounding INR instability. The Prometrium label specifically states it has not been adequately studied in severe hepatic impairment [2], and warfarin is known to require dose reduction in liver disease due to decreased clotting factor synthesis and reduced drug clearance [3].

Postmenopausal vs. Cycling Patients

A woman using Prometrium cyclically (12 days per month) will experience a monthly period of CYP2C9 inhibition followed by a period without it. INR may fluctuate predictably with each cycle. In that scenario, more frequent monitoring during the Prometrium-on phase is appropriate, with recognition that INR may drift back toward the lower end of target during the Prometrium-off days.

Alternative Anticoagulants to Consider

For patients in whom warfarin INR instability on Prometrium becomes difficult to manage, switching to a direct oral anticoagulant (DOAC) may be appropriate if the indication allows. Apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) do not require INR monitoring and have different metabolic pathways. Apixaban uses CYP3A4 and P-glycoprotein; progesterone's mild CYP3A4 inhibitory activity would theoretically produce only minor increases in apixaban exposure, far less clinically significant than the CYP2C9 interaction with warfarin.

The 2019 ACC/AHA atrial fibrillation guideline gave a Class I recommendation for DOACs over warfarin in most non-valvular atrial fibrillation patients [13]. Patients with mechanical heart valves remain on warfarin as the only validated option. For those patients, careful warfarin monitoring with Prometrium, as described above, remains the necessary approach rather than a DOAC switch.

Prescribing Checklist Before Co-Prescribing

Before writing the Prometrium prescription for a patient on warfarin, a clinician should confirm:

• The anticoagulation provider or managing physician has been notified.
• A baseline INR has been checked within the past 7 days and is documented.
• A follow-up INR is scheduled for day 5 to 7 after Prometrium initiation.
• The patient has been counseled on bleeding warning signs.
• No additional CYP2C9 inhibitors or inducers have been added recently.
• The patient's CYP2C9 genotype is known or noted as unknown.
• The indication for Prometrium (endometrial protection, sleep, other) has been documented, because it determines whether dose flexibility exists.

Checking all seven points takes roughly three minutes and substantially reduces the risk of an avoidable supratherapeutic INR event.